These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31912905)

  • 1. Neratinib degrades MST4 via autophagy that reduces membrane stiffness and is essential for the inactivation of PI3K, ERK1/2, and YAP/TAZ signaling.
    Dent P; Booth L; Poklepovic A; Martinez J; Hoff DV; Hancock JF
    J Cell Physiol; 2020 Nov; 235(11):7889-7899. PubMed ID: 31912905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells.
    Dent P; Booth L; Roberts JL; Liu J; Poklepovic A; Lalani AS; Tuveson D; Martinez J; Hancock JF
    Oncogene; 2019 Jul; 38(30):5890-5904. PubMed ID: 31253872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib-resistant NSCLC cells activate ERBB2 and YAP/TAZ and are killed by neratinib.
    Dent P; Booth L; Poklepovic A; Von Hoff D; Martinez J; Zhou Y; Hancock JF
    Biochem Pharmacol; 2021 Aug; 190():114642. PubMed ID: 34077739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced signaling via ERBB3/PI3K plays a compensatory survival role in pancreatic tumor cells exposed to [neratinib + valproate].
    Dent P; Booth L; Poklepovic A; Hoff DV; Hancock JF
    Cell Signal; 2020 Apr; 68():109525. PubMed ID: 31911180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
    Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
    Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAP2 mediates mechanoresponses of the Hippo pathway.
    Meng Z; Qiu Y; Lin KC; Kumar A; Placone JK; Fang C; Wang KC; Lu S; Pan M; Hong AW; Moroishi T; Luo M; Plouffe SW; Diao Y; Ye Z; Park HW; Wang X; Yu FX; Chien S; Wang CY; Ren B; Engler AJ; Guan KL
    Nature; 2018 Aug; 560(7720):655-660. PubMed ID: 30135582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
    Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
    Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
    Chen M; Wang M; Xu S; Guo X; Jiang J
    Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosylphosphorylcholine regulates the Hippo signaling pathway in a dual manner.
    Kemppainen K; Wentus N; Lassila T; Laiho A; Törnquist K
    Cell Signal; 2016 Dec; 28(12):1894-1903. PubMed ID: 27634386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
    Booth L; Poklepovic A; Dent P
    Biochem Pharmacol; 2020 Aug; 178():114067. PubMed ID: 32504550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neratinib augments the lethality of [regorafenib + sildenafil].
    Booth L; Roberts JL; Rais R; Cutler RE; Diala I; Lalani AS; Hancock JF; Poklepovic A; Dent P
    J Cell Physiol; 2019 Apr; 234(4):4874-4887. PubMed ID: 30203445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ.
    Xekouki P; Lodge EJ; Matschke J; Santambrogio A; Apps JR; Sharif A; Jacques TS; Aylwin S; Prevot V; Li R; Flitsch J; Bornstein SR; Theodoropoulou M; Andoniadou CL
    Endocr Relat Cancer; 2019 Jan; 26(1):215-225. PubMed ID: 30139767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.
    Booth L; Roberts JL; Poklepovic A; Kirkwood J; Sander C; Avogadri-Connors F; Cutler RE; Lalani AS; Dent P
    Cancer Biol Ther; 2018 Feb; 19(2):132-137. PubMed ID: 29219657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
    Mana-Capelli S; McCollum D
    J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MST4 kinase suppresses gastric tumorigenesis by limiting YAP activation via a non-canonical pathway.
    An L; Nie P; Chen M; Tang Y; Zhang H; Guan J; Cao Z; Hou C; Wang W; Zhao Y; Xu H; Jiao S; Zhou Z
    J Exp Med; 2020 Jun; 217(6):. PubMed ID: 32271880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MST4-MOB4 complex disrupts the MST1-MOB1 complex in the Hippo-YAP pathway and plays a pro-oncogenic role in pancreatic cancer.
    Chen M; Zhang H; Shi Z; Li Y; Zhang X; Gao Z; Zhou L; Ma J; Xu Q; Guan J; Cheng Y; Jiao S; Zhou Z
    J Biol Chem; 2018 Sep; 293(37):14455-14469. PubMed ID: 30072378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
    Booth L; Roberts JL; Poklepovic A; Dent P
    Front Oncol; 2019; 9():650. PubMed ID: 31380285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.